While ORIC Pharmaceuticals Inc has overperformed by 24.60%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORIC rose by 78.56%, with highs and lows ranging from $14.67 to $3.90, whereas the simple moving average jumped by 65.22% in the last 200 days.
On September 04, 2025, Guggenheim started tracking ORIC Pharmaceuticals Inc (NASDAQ: ORIC) recommending Buy. A report published by Ladenburg Thalmann on July 08, 2025, Initiated its previous ‘Buy’ rating for ORIC. Wells Fargo also rated ORIC shares as ‘Overweight’, setting a target price of $20 on the company’s shares in an initiating report dated October 31, 2024. Stifel Initiated an Buy rating on September 06, 2024, and assigned a price target of $20. Cantor Fitzgerald initiated its ‘Overweight’ rating for ORIC, as published in its report on February 23, 2024. Wedbush’s report from September 22, 2023 suggests a price prediction of $8 for ORIC shares, giving the stock a ‘Outperform’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of ORIC Pharmaceuticals Inc (ORIC)
In order to gain a clear picture of ORIC Pharmaceuticals Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -43.82% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 16.13, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.12M can be a very valuable indicator of volatility for ORIC stock. On a monthly basis, the volatility of the stock is set at 6.42%, whereas on a weekly basis, it is put at 8.12%, with a gain of 24.01% over the past seven days. Furthermore, long-term investors anticipate a median target price of $18.00, showing growth from the present price of $14.41, which can serve as yet another indication of whether ORIC is worth investing in or should be passed over.
How Do You Analyze ORIC Pharmaceuticals Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 42.34%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 63.07% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
